The European Union must deliver funding for research of blood disorders

At the Congress of the European Hematology Association (EHA) – attracting 10,000 hematologists from Europe and beyond - the president of EHA, Prof. Christine Chomienne, called upon the European Union to deliver funding for Research into Blood Disorders:

“The hematologists in Europe have done a great work. Now it’s the EU’s turn to deliver.”

Read more

Training vital for new era of patient-centric healthcare

By European Alliance for Personalised Medicine (EAPM) Executive Director Denis Horgan (Source: EU Reporter Correspondent | June 5, 2015)


“Health-care professionals cannot be expected to adapt to new ways of approaching patients and coping with new technology unless they are suitably trained”, a high-level conference on personalised medicine heard in Brussels this week. 
Delegates were told that it is vital to develop training for professionals whose disciplines are essential to the successful development of personalised medicine to promote the shared understanding and collaborative development of necessary tools.  “To this end, employers, professional organizations, certification entities, regulatory agencies, and others will have to be involved in effecting the necessary changes,” the conference heard.
Read more

Jesus San Miguel presents the Ham-Wasserman Lecture at the 2014 ASH Annual Meeti…

Every year, during the Annual Meeting of the American Society of Hematology, the Ham-Wasserman Lecture is presented. This lectureship was named in honor of two past ASH presidents, the late Dr Thomas Hale Ham and the late Dr Louis R Wasserman. The Ham-Wasserman lecture is traditionally given by an individual from outside the United States who has made a major contribution to our understanding of an area that relates to hematology.

This year Dr Jesus San Miguel was selected for his major contribution in the field of Multiple Myeloma. He will present the Ham-Wasserman Lecture entitled “Multiple Myeloma: A Modern Model for Scientific and Clinical Progress”.


Read more

Announcement: The award winners of the prestigious EHA-ASH Translational Researc…

The European Hematology Association (EHA) congratulates 20 promising young researchers recently selected for the Translational Research Training in Hematology 2015 program. EHA and the American Society of Hematology (ASH) are proud to offer them a rigorous yearlong training, mentoring, and networking program in translational hematological research. TRTH faculty is made up of international leaders in hematology who cover biostatistics and biomarkers, genetics and molecular biology, ethics, and phase I clinical study design. The faculty of the program looks forward to working with the selected trainees on their research proposals, and to build collaborative networks for the future. 

Read more

First Horizon 2020 Work Programme update – budget, and launch of FTI and innovat…

 On July 22, the European Commission announced an update of the Work Programme 2014-2015. Hematologists should be aware that in 2015 opportunities are available to them in the Societal Challenge Health, demographic change and wellbeing.

Read more

The importance of education and collaboration for the treatment of patients

Today, EU Reporter published an article by Ulrich Jäger, past president of the European Hematology Association (EHA) and chair of the European Affairs Committee, highlighting the importance of education and collaboration for the treatment of patients. 

Read more

Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE …

Milan, June 13, 2014 - On Behalf of the RESONATE Investigators, Dr Hillmen will present the results from the Phase III trial in CLL and SLL patients.

Read more

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial acti…

Milan, June 13, 2014 – Promising results from phase-I study for CLL patients will be presented by Dr John Seymour.

Milan, June 13, 2014 – Promising results from phase-I study for CLL patients will be
presented by Dr John SeymourMilan, June 13, 2014 – Promising results from phase-I study or CLL patients will be presented by D
Read more

Do generics of imatinib jeopardize patient safety for the sake of saving money? …

Milan, June 13, 2014 – Dr Zafer Başlar will present the results of a multicenter study that was conducted in Turkey to evaluate the efficacy and tolerability of generics for CML patients.

Read more

Treatment of acute lymphoblastic leukemia by activation of patient's immune cell…

Milan, June 13, 2014 – Dr Nicola Gökbuget will explain also on behalf of Max Topp, the results of two abstracts that will be presented during the 19th Congress of EHA about the treatment of ALL.

Read more

Gdf -11 a new target to improve anemia in thalassemia.

Milan, June 13, 2014 – New possible treatment options for thalassemia patients will be presented by Dr Olivier Hermine at the 19th Congress of EHA.

Read more

Can Eltrombopag help children with ITP say goodbye to bleeding?

Milan, June 13, 2014 – Results from a large international study on pediatric ITP will be presented at the 19th Congress of EHA by Dr John Grainger.

Read more

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

Milan, June 13, 2014 – Dr Alessandro Vannucchi will present the promising results of a Phase III trial for polycythemia vera patients.

Read more

Mutiple Myeloma at the 19th Congress of the European Hematology Association: Wha…

Multiple myeloma (MM), a proliferation (growth) of malignant plasma cells in the bone marrow destroying bones, accounts for 10% of all hematologic malignancies. Approximately 45.000 new cases are diagnosed each year together in the US and Europe. MM is mainly a disease of elderly people with age at diagnosis between 65-70 years.

Read more

Harnessing new developments in genomics to improve outcome for children with poo…

The dramatic improvement in outcome for children with acute lymphoblastic leukemia is one of the major achievements in hematology in the last 40 years. However, while 90% of children with this disease can now be cured, the outlook has not been so good for the less common type of childhood leukemia, acute myeloid leukemia (AML). Although only 1 in 7 children with leukemia have AML, half of these children will die from their disease. The challenge now is to harness the new developments in genomics to improve the outcome for these children.

Read more